Sacituzumab Tirumotecan

Antibody–drug conjugate

Also known as SKB264, MK-2870

Approvedregulatory verdict

Evidence outlook

Approved: Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHR+/HER2- Metastatic Breast Cancer · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USCervical Cancer · Phase 3 · investigational in the USBladder Cancer · Phase 3 · investigational in the USEndometrial Cancer · Phase 3 · investigational in the US

Also approved (2)
CN
  • Unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced settingpharmashots.com
  • EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC after progression on EGFR-TKI therapy and platinum-based chemotherapyseasidesignal.com
Product first approved 2025

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (27)
Bladder Cancer
NCT07829783 · Merck Sharp & Dohme LLC
2026-10-23 – 2036-09-25 · Bladder Cancer
What this study did
NCT07419295 · Merck Sharp & Dohme LLC
2026-04-23 – 2030-04-23 · Bladder Cancer
What this study did
Breast Cancer
NCT07628504 · Fudan University
2026-05-18 – 2035-03-30 · Adjuvant Drug Therapy
What this study did
NCT06279364 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-02-28 – 2028-12 · Triple Negative Breast Cancer
What this study did
Cervical Cancer
Endometrial Cancer
NCT06132958 · Merck Sharp & Dohme LLC
2023-12-06 – 2028-01-10 · Endometrial Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06966700 · Merck Sharp & Dohme LLC
2025-06-30 – 2034-12-29 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
What this study did
Non-Small Cell Lung Cancer
NCT06422143 · Merck Sharp & Dohme LLC
2024-06-10 – 2031-08-15 · Non-small Cell Lung Cancer, NSCLC
What this study did
NCT06074588 · Merck Sharp & Dohme LLC
2023-11-12 – 2030-03-11 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06711900 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-10-30 – 2028-12 · Non-Small Cell Lung Cancer
What this study did
NCT06670196 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-11-27 – 2027-07 · Non-Small Cell Lung Cancer
What this study did
NCT06448312 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-06-07 – 2026-11 · Non-Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT07318558 · Merck Sharp & Dohme LLC
2026-02-16 – 2033-02-25 · Ovarian Neoplasms, Ovarian Cancer
What this study did
NCT06824467 · Merck Sharp & Dohme LLC
2025-04-09 – 2032-11-09 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
Other / comorbidity
NCT06356311 · Merck Sharp & Dohme LLC
2024-05-03 – 2027-05-06 · Gastroesophageal Cancer
What this study did
Phase 2 (80)
Bladder Cancer
NCT07662863 · Fudan University
2026-07-15 – 2029-12-01 · Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
What this study did
Breast Cancer
NCT07109284 · West China Hospital
2025-09 – 2030-12 · ER+HER2- Breast Cancer
What this study did
NCT07371208 · Shanghai Jiao Tong University School of Medicine
2025-12-24 – 2030-08 · Breast Cancer
What this study did
NCT07458113 · Yale University
2026-08 – 2029-08 · Metastatic Triple Negative Breast Cancers
What this study did
NCT07244874 · Tianjin Medical University Cancer Institute and Hospital
2025-12-01 – 2029-07-30 · TNBC - Triple-Negative Breast Cancer, PD-L1 Positive
What this study did
NCT07182721 · Fudan University
2025-09-30 – 2029-02-01 · HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab
What this study did
NCT06849492 · Fudan University
2025-04-01 – 2028-12-31 · Advanced Triple Negative Breast Cancer
What this study did
NCT07054242 · Yantai Yuhuangding Hospital
2025-10-30 – 2028-06-30 · Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
What this study did
NCT07153965 · Tianjin Medical University Cancer Institute and Hospital
2025-09-01 – 2027-09-01 · Triple Negative Breast Cancer (TNBC), PD-L1 Positive
What this study did
NCT07007780 · Xijing Hospital
2025-08-20 – 2027-08-30 · Triple -Negative Breast Cancer
What this study did
Cervical Cancer
NCT07256236 · Fujian Cancer Hospital
2026-01-28 – 2028-12-15 · Cervical Cancer
What this study did
NCT07348861 · Zheng Min
2026-02-01 – 2028-01-01 · Cervical Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07471776 · Fudan University
2026-03-11 – 2029-03-11 · Metastatic Breast Cancer ( HER2 Negative)
What this study did
NCT07466927 · Fudan University
2026-03-15 – 2029-01-15 · HER2-negative Breast Cancer
What this study did
NCT07258108 · Sun Yat-sen University
2025-11-13 – 2028-12-30 · Breast Cancer
What this study did
NCT05445908 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2022-08-17 – 2026-07-31 · Triple-negative Breast Cancer and HR+/HER2- BC
What this study did
Non-Small Cell Lung Cancer
NCT07329322 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-03-30 – 2032-10-31 · Non-Small Cell Lung Cancer
What this study did
NCT06788912 · Merck Sharp & Dohme LLC
2025-03-20 – 2032-02-06 · Lung Neoplasm Malignant
What this study did
NCT07750704 · Guangdong Association of Clinical Trials
2026-09 – 2030-03 · ALK Positive Non-small Cell Lung Cancer
What this study did
NCT06706219 · Hunan Province Tumor Hospital
2026-05-10 – 2029-12-31 · Non Small Cell Lung Cancer (Stage III)
What this study did
NCT07854509 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-10-15 – 2029-12-30 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT07343479 · Zhejiang Cancer Hospital
2026-05-01 – 2029-12-20 · NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
What this study did
NCT07697586 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-08-07 – 2029-08 · NSCLC
What this study did
NCT07197008 · Li-kun Chen
2025-10-01 – 2028-12-30 · Lung Cancer
What this study did
NCT07375316 · Guangdong Association of Clinical Trials
2025-12-15 – 2028-12-30 · Non Small Cell Lung Cancer
What this study did
NCT07789444 · Xiaorong Dong
2026-08-30 – 2028-12-01 · Non-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
What this study did
NCT07819578 · Shaodong Hong
2026-10-01 – 2028-12-01 · Non-Small Cell Lung Cancer
What this study did
NCT05816252 · Klus Pharma Inc.
2023-04-19 – 2028-08-31 · Non-small Cell Lung Cancer
What this study did
NCT07545213 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-04-20 – 2028-08-15 · Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
What this study did
NCT07244926 · Tianjin Medical University Cancer Institute and Hospital
2025-12 – 2028-06 · Lung Cancer
What this study did
NCT07670013 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-04-01 – 2028-06 · NSCLC
What this study did
NCT07703228 · Nanfang Hospital, Southern Medical University
2025-08-13 – 2028-03-13 · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy, Metastases
What this study did
NCT07438600 · Tianjin Medical University Cancer Institute and Hospital
2026-02-24 – 2028-02-28 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT07548060 · Tianjin Medical University Cancer Institute and Hospital
2026-02-01 – 2028-01-22 · NSCLC Stage IV, EGFR Gene Mutation
What this study did
NCT06992739 · The First Affiliated Hospital of Xiamen University
2025-12-08 – 2027-12 · NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
What this study did
NCT07193160 · Fudan University
2025-11-01 – 2027-05-30 · NSCLC (Non-small Cell Lung Cancer)
What this study did
NCT07323056 · Shanghai Pulmonary Hospital, Shanghai, China
2026-01-01 – 2026-12-01 · EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
What this study did
NCT05351788 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2022-05-20 – 2026-12 · Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT07718854 · Tufts Medical Center
2026-09-12 – 2036-09 · Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma
What this study did
NCT07314619 · The First Affiliated Hospital of Zhengzhou University
2025-12-30 – 2027-12-30 · Platinum-resistant Recurrent Ovarian Cancer (PROC)
What this study did
Other / comorbidity
NCT07511023 · M.D. Anderson Cancer Center
2026-09-25 – 2033-03-01 · Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ Rectum
What this study did
NCT07639086 · Virginia Commonwealth University
2026-08-31 – 2032-03-31 · Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
What this study did
NCT07928193 · Latin American Cooperative Oncology Group
2027-03 – 2032-03 · Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary Gland
What this study did
NCT07804966 · Latin American Cooperative Oncology Group
2027-01 – 2032-01 · Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma
What this study did
NCT07785609 · Merck Sharp & Dohme LLC
2026-10-07 – 2031-09-30 · Advanced Solid Tumors, Malignant Neoplasm
What this study did
NCT07823270 · Hebei Medical University Fourth Hospital
2026-10 – 2030-12 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07750353 · National Cancer Center, Japan
2027-02-01 – 2030-06 · Unresectable Thymic Carcinoma
What this study did
NCT07438626 · M.D. Anderson Cancer Center
2026-04-27 – 2030-02-01 · Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
What this study did
Phase 1/2 (14)
Bladder Cancer
NCT06637423 · Merck Sharp & Dohme LLC
2024-12-20 – 2026-09-30 · Non-Muscle Invasive Bladder Cancer
What this study did
Breast Cancer
NCT07139470 · Tianjin Medical University Cancer Institute and Hospital
2025-08-15 – 2027-10-15 · Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd.
2026-07-28 – 2030-08-01 · Breast Cancer (Locally Advanced or Metastatic)
What this study did
NCT04152499 · Klus Pharma Inc.
2020-02-28 – 2027-11-30 · Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07286149 · Merck Sharp & Dohme LLC
2026-04-30 – 2032-04-13 · Lung Neoplasm Malignant
What this study did
Other / comorbidity
NCT07908524 · Merck Sharp & Dohme LLC
2026-12-14 – 2032-06-29 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06780111 · Merck Sharp & Dohme LLC
2025-07-30 – 2032-01-04 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07586943 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2026-06-01 – 2030-12 · Advanced Solid Tumors
What this study did
NCT06445972 · Merck Sharp & Dohme LLC
2024-08-07 – 2030-08-08 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT06428409 · Merck Sharp & Dohme LLC
2024-06-20 – 2029-10-16 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
What this study did
NCT06469944 · Merck Sharp & Dohme LLC
2024-09-20 – 2029-09-12 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
What this study did
NCT07157956 · Convalife (Shanghai) Co., Ltd.
2025-09-10 – 2028-12-30 · Advanced Solid Tumor
What this study did
NCT06483334 · Merck Sharp & Dohme LLC
2024-07-17 – 2028-03-31 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT06049212 · Merck Sharp & Dohme LLC
2023-10-26 – 2028-01-29 · Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
What this study did
NCT07702305 · Henan Cancer Hospital
2026-06-23 – 2027-12-31 · EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07068542 · Zhejiang Provincial People's Hospital
2025-07-01 – 2028-12-31 · Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT07895992 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-11-30 – 2030-12-30 · Non-squamous Non-small Cell Lung Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Other / comorbidity
NCT07778368 · Shanghai East Hospital
2026-09-01 – 2029-08-31 · Oral Squamous Cell Carcinoma (OSCC)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sacituzumab Tirumotecan: this drugPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Enfortumab VedotinApprovedAntibody–drug conjugateNectin-4Partial signal
NCT03474107: Overall Survival (OS) (From randomization until the analysis cut-off date of 15-Jul-2020 (median OS follow-up was 11.10 months)): Enfortumab Vedotin 1.25 mg/kg 12.88 months (95% CI 10.58 to 15.21) | Chemotherapy 8.97 months (95% CI 8.05 to 10.74)
NCT03219333: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) (Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)): Enfortumab Vedotin - Cohort 1 44 Percentage of Participants (95% CI 35.1 to 53.2) | Enfortumab Vedotin - Cohort 2 51.7 Percentage of Participants (95% CI 40.8 to 62.4)
Nogapendekin Alfa Inbakicept (Anktiva)ApprovedProtein / enzyme therapeuticIL-15 superagonistnot yet gradedNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
TremelimumabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
VisugromabPhase 2Monoclonal antibodyGDF-15Weak signal
NCT06059547: Two primary endpoints, no significance test reported (exploratory). Pathologic complete response: 33.3% nivolumab + visugromab (n=15 evaluable) vs 7.1% nivolumab + placebo (n=14 evaluable). Objective response by RECIST 1.1: 60.0% vs 14.3%. Major pathologic response (secondary): 66.7% vs 21.4%.
MK-3120Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
SHR-2005Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
TuvutromstatPhase 1Small moleculeMAT2Anot yet gradedNo reviewed efficacy summary in this indication
Avipendekin Pegol
—(overall)
CytokineIL-15 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(111 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sacituzumab Tirumotecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch
December 2026 (5)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07108816 · CT.gov ↗
What to watch
Phase 2Selected Subjects With Advanced Solid TumorsActive not recruiting
Est. primary completion 2026-12-30 · NCT05631262 · CT.gov ↗
What to watch
Phase 2Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07579598 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗
What to watch
2027 (38)
January 2027 (2)
Phase 2TNBC, Brain MetastasisRecruiting
Est. primary completion 2027-01 · NCT07623577 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2027-01-01 · NCT07561463 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Extensive-Stage Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT07388875 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03 · NCT06992739 · CT.gov ↗
What to watch
April 2027 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT06279364 · CT.gov ↗
What to watch
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT07139470 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05 · NCT06670196 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-10 · NCT06074588 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07244926 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-20 · NCT07343479 · CT.gov ↗
What to watch
Phase 2Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant …Recruiting
Est. primary completion 2027-06-30 · NCT07179783 · CT.gov ↗
What to watch
July 2027 (7)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT07105852 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract Cancer(BTC)Not yet recruiting
Est. primary completion 2027-07-01 · NCT07701122 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07789444 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Neoplasms (Tumours)Not yet recruiting
Est. primary completion 2027-07-20 · NCT07077564 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT07258108 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07088211 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Not yet recruiting
Est. primary completion 2027-08-31 · NCT07501169 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07689292 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT07703228 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
December 2027 (12)
Phase 2Advanced Biliary Tract CancersNot yet recruiting
Est. primary completion 2027-12 · NCT07729033 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT07939204 · CT.gov ↗
What to watch
Phase 2Thymic Epithelial Tumors, Advanced Stage, Second-line TherapyNot yet recruiting
Est. primary completion 2027-12-22 · NCT07343453 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07197008 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07314619 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07854509 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07702305 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06049212 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Head and Neck CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07686588 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07811752 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07068542 · CT.gov ↗
What to watch
2028 (35)
January 2028 (9)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07109284 · CT.gov ↗
What to watch
Phase 2Ovarian Epithelial CancerActive not recruiting
Est. primary completion 2028-01 · NCT07341100 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT07670013 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07348861 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2028-01-10 · NCT06132958 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-22 · NCT07548060 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02-15 · NCT07545213 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-03 · NCT07815197 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗
What to watch
Phase 1/2Metastatic Urothelial Carcinoma, Locally Advanced Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Thymic CarcinomaRecruiting
Est. primary completion 2028-04 · NCT07324629 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
June 2028 (4)
Phase 2Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary CarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07438626 · CT.gov ↗
What to watch
Phase 3Cervical CancerActive not recruiting
Est. primary completion 2028-06-15 · NCT06459180 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2028-06-30 · NCT07256236 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT07375316 · CT.gov ↗
What to watch
August 2028 (5)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08 · NCT07371208 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07458113 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), GC/GEJCNot yet recruiting
Est. primary completion 2028-09-01 · NCT07701681 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic MSI-H/dMMR Gynecological MalignanciesNot yet recruiting
Est. primary completion 2028-09-01 · NCT07738757 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07182721 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-10 · NCT07850791 · CT.gov ↗
What to watch
Phase 2Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07521670 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗
What to watch
December 2028 (5)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07128693 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07823270 · CT.gov ↗
What to watch
Phase 2Bladder CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07662863 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07819578 · CT.gov ↗
What to watch
Phase 2Advanced Small Bowel AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07720258 · CT.gov ↗
What to watch
2029 (13)
January 2029 (2)
Phase 2Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07907861 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2029-07-27 · NCT07419295 · CT.gov ↗
What to watch
August 2029 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07750704 · CT.gov ↗
What to watch
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Papillary Renal Carcinoma, Variant Histology Urothelial CarcinomaNot yet recruiting
Est. primary completion 2029-10 · NCT07716917 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract CancerRecruiting
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-12 · NCT07586943 · CT.gov ↗
What to watch
Phase 2Unresectable Thymic CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07750353 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 2Ovarian Clear Cell CarcinomaNot yet recruiting
Est. primary completion 2030-01-31 · NCT07913568 · CT.gov ↗
What to watch
March 2030 (3)
Phase 2Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-03 · NCT07804966 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2030-03-30 · NCT07628504 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)Not yet recruiting
Est. primary completion 2030-03-31 · NCT07639086 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Salivary Gland Cancers, Adenoid Cystic Carcinoma of the Salivary GlandNot yet recruiting
Est. primary completion 2030-04 · NCT07928193 · CT.gov ↗
What to watch
May 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
2031 (4)
March 2031 (1)
Phase 2Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ RectumNot yet recruiting
Est. primary completion 2031-03-01 · NCT07511023 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Advanced Solid Tumors, Malignant NeoplasmRecruiting
Est. primary completion 2031-09-30 · NCT07785609 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Cervical CancerRecruiting
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
2032 (4)
January 2032 (1)
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
June 2032 (1)
Phase 1/2Metastatic Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2032-06-29 · NCT07908524 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2033-02-25 · NCT07318558 · CT.gov ↗
What to watch
March 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch
2036 (1)
September 2036 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2036-09 · NCT07718854 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 July 2026Filing acceptedNMPA accepts the new indication application for sac-TMT in first-line advanced TNBC
China, NMPA · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Source ↗